Top

Journal of Cancer Research and Clinical Oncology

Published in:

Open Access 01-12-2017 | Letter to the Editor

To block it, or not to block it?

Author: Artur Wnorowski

Published in: Journal of Cancer Research and Clinical Oncology | Issue 12/2017

Excerpt

To Editor, …

Barron TI, Connolly RM, Sharp L, Bennett K, Visvanathan K (2011) Beta blockers and breast cancer mortality: a population-based study. J Clin Oncol Off J Am Soc Clin Oncol 29:2635–2644. doi:10.1200/JCO.2010.33.5422 CrossRef

Bruzzone A, Sauliere A, Finana F, Senard JM, Luthy I, Gales C (2014) Dosage-dependent regulation of cell proliferation and adhesion through dual β2-adrenergic receptor/cAMP signals. FASEB J 28:1342–1354. doi:10.1096/fj.13-239285 CrossRefPubMed

Carie AE, Sebti SM (2007) A chemical biology approach identifies a beta-2 adrenergic receptor agonist that causes human tumor regression by blocking the Raf-1/Mek-1/Erk1/2 pathway. Oncogene 26:3777–3788. doi:10.1038/sj.onc.1210172 CrossRefPubMed

Chen TC, Hinton DR, Zidovetzki R, Hofman FM (1998) Up-regulation of the cAMP/PKA pathway inhibits proliferation, induces differentiation, and leads to apoptosis in malignant gliomas. Lab Invest 78:165–174PubMed

Coelho M, Soares-Silva C, Brandao D, Marino F, Cosentino M, Ribeiro L (2017) β-Adrenergic modulation of cancer cell proliferation: available evidence and clinical perspectives. J Cancer Res Clin Oncol 143:275–291 doi:10.1007/s00432-016-2278-1 CrossRefPubMed

Eskander R, Bessonova L, Chiu C, Ward K, Culver H, Harrison T, Randall L (2012) Beta blocker use and ovarian cancer survival: a retrospective cohort study. Gynecol Oncol 127:S21 doi:10.1016/j.ygyno.2012.07.059 CrossRef

Gargiulo L et al (2014) Differential beta(2)-adrenergic receptor expression defines the phenotype of non-tumorigenic and malignant human breast cell lines. Oncotarget 5:10058–10069CrossRefPubMedPubMedCentral

Hilal-Dandan R, Knollman B, Brunton L (2017) Goodman and Gilman’s The Pharmacological Basis of Therapeutics, 13th Edition. McGraw-Hill Education

Johannesdottir SA, Schmidt M, Phillips G, Glaser R, Yang EV, Blumenfeld M, Lemeshow S (2013) Use of β-blockers and mortality following ovarian cancer diagnosis: a population-based cohort study. BMC Cancer 13:85. doi:10.1186/1471-2407-13-85 CrossRefPubMedPubMedCentral

Lemeshow S et al (2011) beta-Blockers and survival among Danish patients with malignant melanoma: a population-based cohort study. Cancer Epidemiol Biomarkers Prev 20:2273–2279. doi:10.1158/1055-9965.EPI-11-0249 CrossRefPubMedPubMedCentral

Schmidt SA, Schmidt M (2016) Beta-blockers and improved survival from ovarian cancer: New miracle treatment or another case of immortal person-time bias? Cancer 122:324–325. doi:10.1002/cncr.29721 CrossRefPubMed

Skalhegg BS, Tasken K (2000) Specificity in the cAMP/PKA signaling pathway. Differential expression, regulation, and subcellular localization of subunits of PKA. Front Biosci J Virtual Library 5:D678–D693

Strell C, Niggemann B, Voss MJ, Powe DG, Zanker KS, Entschladen F (2012) Norepinephrine promotes the beta1-integrin-mediated adhesion of MDA-MB-231 cells to vascular endothelium by the induction of a GROalpha release. Mol Cancer Res MCR 10:197–207. doi:10.1158/1541-7786.MCR-11-0130 CrossRefPubMed

Suissa S (2008) Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 167:492–499. doi:10.1093/aje/kwm324 CrossRefPubMed

Sullivan KG, Levin M (2016) Neurotransmitter signaling pathways required for normal development in Xenopus laevis embryos: a pharmacological survey screen. J Anatomy 229:483–502 doi:10.1111/joa.12467 CrossRef

Sun F et al (2015) β2-Adrenoreceptor-mediated proliferation inhibition of embryonic pluripotent stem cells. J Cell Physiol 230:2640–2646. doi:10.1002/jcp.24937 CrossRefPubMed

Toll L et al (2011) β2-adrenergic receptor agonists inhibit the proliferation of 1321N1 astrocytoma cells. J Pharmacol Exp Ther 336:524–532. doi:10.1124/jpet.110.173971 CrossRefPubMedPubMedCentral

Watkins JL et al (2015) Clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer. Cancer 121:3444–3451. doi:10.1002/cncr.29392 CrossRefPubMedPubMedCentral

Weberpals J, Jansen L, Carr PR, Hoffmeister M, Brenner H (2016) Beta blockers and cancer prognosis—the role of immortal time bias: a systematic review and meta-analysis. Cancer Treatment Rev 47:1–11 doi:10.1016/j.ctrv.2016.04.004 CrossRef

Wnorowski A, Jozwiak K (2014) Homo- and hetero-oligomerization of β2-adrenergic receptor in receptor trafficking, signaling pathways and receptor pharmacology. Cell Signal 26:2259–2265. doi:10.1016/j.cellsig.2014.06.016 CrossRefPubMed

Wnorowski A et al (2015) Activation of β2-adrenergic receptor by (R,R′)-4′-methoxy-1-naphthylfenoterol inhibits proliferation and motility of melanoma cells. Cell Signal 27:997–1007. doi:10.1016/j.cellsig.2015.02.012 CrossRefPubMedPubMedCentral

Title: To block it, or not to block it?
Author: Artur Wnorowski
Publication date: 01-12-2017
Publisher: Springer Berlin Heidelberg
Published in: Journal of Cancer Research and Clinical Oncology / Issue 12/2017
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-017-2400-z

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

To block it, or not to block it?

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 12/2017

Identification of prognostic markers of high grade prostate cancer through an integrated bioinformatics approach

Lenalidomide in combination with bendamustine and prednisolone in relapsed/refractory multiple myeloma: results of a phase 2 clinical trial (OSHO-#077)

Can complementary medicine increase adherence to chemotherapy dosing protocol? A controlled study in an integrative oncology setting

Reviewer Acknowledgements 2017

Tumor response assessment: comparison between unstructured free text reporting in routine clinical workflow and computer-aided evaluation based on RECIST 1.1 criteria

TLR9 gene polymorphism −1486T/C (rs187084) is associated with uterine cervical neoplasm in Mexican female population

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page